Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -132.16% is 678% below its 5-year average of 22.85%, near the low end of its 5-year range (-132.16%–496.70%).
As of the fiscal period ended Wednesday, December 31, 2025. 77.25% below its 12-month average of -74.56%.
Annual fiscal-year return on equity; no daily interpolation. Historical series through 2025-12-31.
RETURN ON EQUITY (ROE)
-132.16%
RETURN ON EQUITY (ROE) AVG TTM
-74.56%
RETURN ON EQUITY (ROE) AVG 3Y
-71.32%
RETURN ON EQUITY (ROE) AVG 5Y
22.85%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-77.25%
CURRENT VS 3Y AVG
-85.30%
CURRENT VS 5Y AVG
-678.30%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.56%
median of 492 covered companies
CURRENT VS SECTOR MEDIAN
-242.74%
vs the sector median at left
Connect Biopharma Holdings Limited
Market Cap
$56.10M
Return on Equity (ROE)
-132.16%
TTM Avg
-74.56%
3Y Avg
-71.32%
5Y Avg
22.85%
Market Cap
$54.90M
Return on Equity (ROE)
N/A
TTM Avg
-382.07%
3Y Avg
-282.25%
5Y Avg
-171.00%
Market Cap
$57.33M
Return on Equity (ROE)
N/A
TTM Avg
171.70%
3Y Avg
384.85%
5Y Avg
251.73%
Market Cap
$58.66M
Return on Equity (ROE)
-58.99%
TTM Avg
-51.19%
3Y Avg
-1.82%
5Y Avg
11.74%
Market Cap
$58.97M
Return on Equity (ROE)
N/A
TTM Avg
-866.00%
3Y Avg
-422.47%
5Y Avg
-312.54%
Market Cap
$58.83M
Return on Equity (ROE)
-60.85%
TTM Avg
-77.57%
3Y Avg
-56.89%
5Y Avg
-53.13%
Market Cap
$53.13M
Return on Equity (ROE)
-52.72%
TTM Avg
-32.48%
3Y Avg
-92.81%
5Y Avg
-85.98%
Market Cap
$53.01M
Return on Equity (ROE)
-36.94%
TTM Avg
-31.55%
3Y Avg
-37.51%
5Y Avg
-20.44%
Market Cap
$52.99M
Return on Equity (ROE)
N/A
TTM Avg
31.64%
3Y Avg
119.26%
5Y Avg
-26.51%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Connect Biopharma Holdings Limited (CNTB) | $56.10M | -132.16% | -74.56% | -71.32% | 22.85% |
| Apollomics, Inc. (APLM)vs › | $54.90M | N/A | -382.07% | -282.25% | -171.00% |
| Spectral AI, Inc. (MDAI)vs › | $57.33M | N/A | 171.70% | 384.85% | 251.73% |
| Boundless Bio, Inc. (BOLD)vs › | $58.66M | -58.99% | -51.19% | -1.82% | 11.74% |
| Fractyl Health, Inc. (GUTS)vs › | $58.97M | N/A | -866.00% | -422.47% | -312.54% |
| Aldeyra The (ALDX)vs › | $58.83M | -60.85% | -77.57% | -56.89% | -53.13% |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $53.13M | -52.72% | -32.48% | -92.81% | -85.98% |
| ImageneBio Inc (IMA)vs › | $53.01M | -36.94% | -31.55% | -37.51% | -20.44% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $52.99M | N/A | 31.64% | 119.26% | -26.51% |
| MiNK Therapeutics, Inc. (INKT)vs › | $59.51M | N/A | 71.44% | 1810.59% | 1190.90% |
ROE
-132.2%
ROA
-98.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -132.16% |
| 2024-12-31 | -16.96% |
| 2023-12-31 | -61.19% |
| 2022-12-31 | -74.98% |
| 2021-12-31 | -74.29% |
| 2020-12-31 | 496.70% |
| 2019-12-31 | 395.54% |
| 2018-12-31 | 0.00% |
